Article Figures & Data
Figures
- Figure 1
- peripheral blood stem cell mobilization and collection (± preemtive plerixafor).
Tables
Parameters Overall HL NHL MM Patients number 215 (100) 86 (40.0) 63 (29.3) 66 (30.7) Gender #x00A0; #x00A0; #x00A0; #x00A0; Male 144 (67.0) 57 (66.3) 43 (68.3) 44 (66.7) Female 71 (33.0) 29 (33.7) 20 (31.7) 22 (33.3) Age (years) at PBSC collection, median (range) 40 (14-69) 27 (14-55) 42 (16-62) 53 (27-69) Body weight (kg) at PBSC collection, median (range) 71 (31-149) 67 (31-149) 74 (40-124) 72 (52-131) Specification diagnosis, n #x00A0; #x00A0; DLBCL= 38 MM= 63 ALCL= 8 POEMS= 3 TCL= 5 BL= 4 MCL= 3 FL= 2 Others= 3 Data are presented as number and precentage (%). MM: multiple myeloma, PBSC: peripheral blood stem cell, DLBCL: diffuse large B-cell lymphoma, ALCL: anaplastic large cell lymphoma, TCL: T-cell lymphoma, BL: Burkitt’s lymphoma, MCL: mantle cell lymphoma, FL: follicular lymphoma, HL: Hodgkin’s lymphoma, NHL: non-Hodgkin’s lymphoma, POEMS: polyneuropathy organomegaly endocrinopathy monoclonal protein skin changes
- Table 2
- Parameters and results of peripheral blood stem cells mobilization and collection.
Parameters Overall HL NHL MM Patients number 215 (100) 86 (40) 63 (29.3) 66 (30.7) Blood count pre-collection LP1, median (range) WBC × 109/L 15 (3.1-97) 21 (3.4-81.9) 13.1 (3.1-97) 12.3 (4.1-73.8) MNC% 21.1 (3.7-88) 16.8 (4.7-31.6) 26.7 (3.7-74.7) 18.8 (5.1-88) Mobilization regimens Cyclophosphamide 61 (28.4) 1 (1.2) 1 (1.6) 59 (89.4) ESHAP/R-ESHAP 64 (29.8) 30 (34.9) 34 (54.0) - IGEV/R-IGEV 7 (3.3) 5 (5.8) 2 (3.2) - GDP 6 (2.8) 5 (5.8) 1 (1.6) - R-ICE 4 (1.9) - 4 (6.3) - DHAP/R-DHAP 2 (0.9) - 2 (3.2) - CHOP/R-CHOP 1 (0.4) - 1 (1.6) - Cytrabine + Etoposide 5 (2.3) - 5 (7.9) - Other chemo-mobilizations 3 (1.4) 1 (1.2) 1 (1.6) 1 (1.5) G-CSF only 62 (28.8) 44 (51.1) 12 (19.0) 6 (9.1) Plerixafor administration Yes 29 (13.5) 13 (15.1) 9 (14.3) 7 (10.6) No 186 (86.5) 73 (84.9) 54 (85.7) 59 (89.4) PBSC collection, PB CD34+ cells/µL at maximum stimulation, median (range) 61 (0-1367) 48 (1-735) 56 (0-1367) 76 (3-304) PB CD34+ cells/µL at day 1 of LP, median (range) 63 (9-1367) 60 (11-735) 62 (10-1367) 79 (9-304) Peak CD34+ cells (<10/µL) in PB 24 (11.2) 11 (12.8) 9 (14.3) 4 (6.1) Peak CD34+ cells (10-<20/µL) in PB 20 (9.3) 8 (9.3) 7 (11.1) 5 (7.6) Peak CD34+ cells (≥20/µL) in PB 171 (79.5) 67 (77.9) 47 (74.6) 57 (86.3) Patients with 2 LP sessions 37 (17.2) 14 (16.3) 11 (17.5) 12 (18.2) CD34+ cells collection ×106/kg (BW), median (range) 5.1 (2.03-66.2) 4.5 (2.19-66.2) 4.6 (2.03-30.7) 6.6 (2.77-18.75) Overall processed TBV, mean±SD 2.2 (0.62) 1.9 (0.49) 2.2 (0.65) 2.2 (0.62) Failed first pre-emptive dosing of plerixafor 5 (2.3) 3 (3.5) 2 (3.2) 0 (0.0) Failure of PBSC mobilization 1 (0.5) 0 (0.0) 1 (1.6) 0 (0.0) Data are presented as number and percentage (%). HL: Hodgkin’s lymphoma, NHL: non-Hodgkin’s lymphoma, MM: multiple myeloma, LP1: leukapheresis-1, WBC: white blood cell, MNC: mononuclear blood cells, R-ESHAP: rituximab, etoposide, methylprednisolone, cytarabine, and cisplatin, R- IGEV: rituximab, ifosfamide, gemcitabine, and vinorelbine, GDP: gemcitabine, dexamethasone, and cisplatin, R-ICE: rituximab, etoposide, ifosfamide, and carboplatin, R-DHAP: rituximab, dexamethasone, cisplatin, and cytarabine, R-CHOP: rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, G-CSF: granulocyte colony-stimulating factor, PBSC: peripheral blood stem cell, PB: peripheral blood, LP: leukapheresis, BW: body weight, TBV: total blood volume
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.